Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 14 results

] Title Type Year

Filters: Keyword is Colitis, Ulcerative [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

B

Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al.. 2017. Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.

Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A. 2014. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.. Inflamm Bowel Dis. 20(6):1120-8.

D

Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. 2015. Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.

Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al.. 2014. Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al.. 2020. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.

F

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al.. 2019. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.

G

Gogokhia L, Buhrke K, Bell R, Hoffman B, D Brown G, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF et al.. 2019. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.. Cell Host Microbe. 25(2):285-299.e8.

J

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al.. 2017. Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.

K

Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B. 2013. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.

L

Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS. 2020. Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.

M

Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T. 2013. S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.

N

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al.. 2018. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.

P

Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al.. 2020. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.

S

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al.. 2018. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.